Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Eric Benevich also recently made the following trade(s):
- On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.
Neurocrine Biosciences Price Performance
Neurocrine Biosciences stock traded up $0.24 during trading on Wednesday, reaching $133.23. 571,073 shares of the company were exchanged, compared to its average volume of 851,005. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The company has a market capitalization of $13.26 billion, a P/E ratio of 55.45 and a beta of 0.25. The stock’s 50 day simple moving average is $136.25 and its two-hundred day simple moving average is $126.77.
Wall Street Analysts Forecast Growth
NBIX has been the topic of a number of recent analyst reports. Barclays increased their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Wells Fargo & Company increased their price target on Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 8th. Finally, Citigroup decreased their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $139.67.
Check Out Our Latest Stock Report on Neurocrine Biosciences
Institutional Investors Weigh In On Neurocrine Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Neurocrine Biosciences by 14.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,805 shares of the company’s stock valued at $939,000 after buying an additional 853 shares during the period. Toth Financial Advisory Corp raised its holdings in shares of Neurocrine Biosciences by 34.6% in the 1st quarter. Toth Financial Advisory Corp now owns 5,500 shares of the company’s stock valued at $759,000 after buying an additional 1,413 shares during the period. Chesley Taft & Associates LLC purchased a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at $1,034,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Neurocrine Biosciences by 48.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,744 shares of the company’s stock valued at $654,000 after buying an additional 1,550 shares during the period. Finally, Park Avenue Securities LLC raised its holdings in shares of Neurocrine Biosciences by 1.1% in the 1st quarter. Park Avenue Securities LLC now owns 9,570 shares of the company’s stock valued at $1,320,000 after buying an additional 101 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Articles
- Five stocks we like better than Neurocrine Biosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- United Airlines Soars on Earnings Beat
- How to Calculate Options Profits
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Why Invest in High-Yield Dividend Stocks?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.